Screener
Royalty Pharma RPRX JNJ‑4804 — Unfunded Commitments
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept rprx:ResearchAndDevelopmentUnfundedCommitments.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Product Candidates | Counterparties | Total Commitments | Funding Timing | Unfunded Commitments |
|---|---|---|---|---|
| JNJ‑4804 | Johnson & Johnson | $500,000 | Eight fixed quarterly payments commencing in the second quarter of 2026 | $437,500 |
| TEV-’408(1) | Teva Pharmaceuticals | 75,000 | Variable quarterly payments commencing in second quarter of 2026 | 65,149 |
| Litifilimab | Biogen | 250,000 | Six fixed quarterly payments commencing in first quarter of 2025 | — |
| Total | $825,000 | $502,649 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's JNJ‑4804 — unfunded commitments?
- Royalty Pharma (RPRX) reported JNJ‑4804 — unfunded commitments of $437.5M in Q2 2026.
- What does JNJ‑4804 — unfunded commitments mean?
- This metric measures the portion of the total contractual commitment for the JNJ-4804 asset that has not yet been paid out or deployed by the company. It represents future cash outflows required to satisfy existing investment agreements as specific milestones or conditions are met. Monitoring this figure is essential for assessing near-term liquidity requirements and future capital deployment obligations.
Ask your AI about Royalty Pharma's jnj‑4804 — unfunded commitments.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude